174 related articles for article (PubMed ID: 27919177)
1. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Med Econ; 2017 Apr; 20(4):353-362. PubMed ID: 27919177
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
4. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.
Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT; Doshi JA
J Med Econ; 2014 Feb; 17(2):148-58. PubMed ID: 24168640
[TBL] [Abstract][Full Text] [Related]
5. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.
Buono JL; Carson RT; Flores NM
Health Qual Life Outcomes; 2017 Feb; 15(1):35. PubMed ID: 28196491
[TBL] [Abstract][Full Text] [Related]
7. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
[TBL] [Abstract][Full Text] [Related]
9. Direct costs of carcinoid syndrome diarrhea among adults in the United States.
Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
World J Gastroenterol; 2019 Dec; 25(47):6857-6865. PubMed ID: 31885426
[TBL] [Abstract][Full Text] [Related]
10. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea.
Lacy BE; Gagnon-Sanschagrin P; Heimanson Z; Bungay R; Bellefleur R; Guérin A; Bumpass B; Borroto D; Joseph G; Dashputre AA
Adv Ther; 2024 Jun; 41(6):2253-2266. PubMed ID: 38619720
[TBL] [Abstract][Full Text] [Related]
11. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.
Broder MS; Chang E; Romanus D; Cherepanov D; Neary MP
World J Gastroenterol; 2016 Feb; 22(6):2118-25. PubMed ID: 26877616
[TBL] [Abstract][Full Text] [Related]
12. The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease.
Hong YD; Onukwugha E; Slejko JF
J Manag Care Spec Pharm; 2020 Oct; 26(10):1353-1362. PubMed ID: 32996389
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
14. Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.
Lacy BE; Chey WD; Cash BD; Lembo AJ; Dove LS; Covington PS
Am J Gastroenterol; 2017 Jun; 112(6):924-932. PubMed ID: 28417992
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based management of irritable bowel syndrome with diarrhea.
Pimentel M
Am J Manag Care; 2018 Jan; 24(3 Suppl):S35-S46. PubMed ID: 29372991
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
17. [Clinical effect of abdominal acupuncture for diarrhea irritable bowel syndrome].
Qin Y; Yi W; Lin S; Yang C; Zhuang Z
Zhongguo Zhen Jiu; 2017 Dec; 37(12):1265-8. PubMed ID: 29354989
[TBL] [Abstract][Full Text] [Related]
18. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
[TBL] [Abstract][Full Text] [Related]
19. Impact of symptom severity in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D): results from two separate surveys of HCPs and patients with IBS-D.
Emmanuel A; Goosey RW; Wiseman G; Baker S; Törnblom H
BMC Gastroenterol; 2020 Apr; 20(1):127. PubMed ID: 32336287
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers.
Almario CV; Noah BD; Jusufagic A; Lew D; Spiegel BMR
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1434-1441.e21. PubMed ID: 29596984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]